DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Ecopipam is an investigational drug.
There have been 10 clinical trials for Ecopipam. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2012.
The most common disease conditions in clinical trials are Syndrome, Tourette Syndrome, and Self-Injurious Behavior. The leading clinical trial sponsors are Psyadon Pharma, Emalex Biosciences Inc., and William Ondo, MD.
There are eleven US patents protecting this investigational drug and two hundred and ninety-eight international patents.
Recent Clinical Trials for Ecopipam
|Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension||Emalex Biosciences Inc.||Phase 2|
|Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents||Emalex Biosciences Inc.||Phase 2|
|Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist||Restless Legs Syndrome Foundation||Phase 1/Phase 2|
Top disease conditions for Ecopipam
Top clinical trial sponsors for Ecopipam
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ecopipam||Start Trial||Tape preparation of WT1 peptide cancer vaccine for transdermal administration||NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP)||Start Trial|
|Ecopipam||Start Trial||WT1 peptide cancer vaccine composition for mucosal administration||NITTO DENKO CORPORATION (Osaka, JP) OSAKA UNIVERSITY (Osaka, JP)||Start Trial|
|Ecopipam||Start Trial||Process for synthesis of D1 receptor antagonists||Schering Corporation (Kenilworth, NJ)||Start Trial|
|Ecopipam||Start Trial||Active agent delivery systems and methods for protecting and administering active agents||New River Pharmaceuticals Inc. (Radford, VA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ecopipam||European Patent Office||2762156||2033-02-05||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|